Actuate Therapeutics, Inc (NASDAQ:ACTU) IPO will take place July, 24 on the NASDAQ exchange under the ticker ACTU.

The company is offering shares at an expected price between $8.00 and $10.00 per share with an insider lock-up period of 180 days ending on January 20, 2025.

See also: Benzinga IPO Calendar

About Actuate Therapeutics, Inc

Actuate Therapeutics, Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3

See also: Benzinga's Most Shorted Stocks

This article was generated by Benzinga's automated content engine and reviewed by an editor.